title: Safety and persistence of orally administered human Lactobacillus sp. strains in healthy adults.
abstract: The aim of the study was to evaluate the safety and persistence of selected Lactobacillus strains in the gastrointestinal tract (GIT) of healthy adult volunteers after oral consumption of high doses of lactobacilli to identify potential candidates for probiotic and biotechnological applications. In the first phase of the study, nine individuals consumed capsules containing Lactobacillus gasseri 177 and E16B7, Lactobacillus acidophilus 821-3, Lactobacillus paracasei 317 and Lactobacillus fermentum 338-1-1 (each daily dose 1×1010 cfu) for 5 consecutive days. Data on gut health, blood parameters, and liver and kidney function were collected. The persistence of Lactobacillus strains was assessed by culturing combined with arbitrarily primed polymerase chain reaction (AP-PCR) and PCR-denaturing gradient gel electrophoresis (PCR-DGGE) on days 0, 5, 8, 10 and 20 from faecal samples. All strains survived gastrointestinal passage and were detected on the 5th day. L. acidophilus 821-3 was detected in four volunteers on the 8th day (4.3 to 7.0 log10 cfu/g) and in two on the 10th day (8.3 and 3.9 log10 cfu/g, respectively). In the second phase of the study, five additional volunteers consumed L. acidophilus 821-3 (daily 1×1010 cfu) for 5 consecutive days. The strain was subsequently detected in faeces of all individuals using real-time PCR on the 10th day (range 4.6-6.7; median 6.0 log10 cell/g) in both phases of the study for at least 5 days after discontinuation of consumption. The administration of high doses of different Lactobacillus strains did not result in any severe adverse effects in GIT and/or abnormal values of blood indices. Thus, the strain L. acidophilus 821-3 is a promising candidate for probiotic and biotechnological applications. Further studies will be performed to confirm the strain persistence and safety in a larger number of individuals.
authors.affiliation: Department of Microbiology, University of Tartu, Estonia. pirje.hutt@ut.ee
authors.forename: P
authors.initials: P
authors.lastname: Hütt
authors.forename: P
authors.initials: P
authors.lastname: Kõll
authors.forename: J
authors.initials: J
authors.lastname: Stsepetova
authors.forename: B
authors.initials: B
authors.lastname: Alvarez
authors.forename: R
authors.initials: R
authors.lastname: Mändar
authors.forename: K
authors.initials: K
authors.lastname: Krogh-Andersen
authors.forename: H
authors.initials: H
authors.lastname: Marcotte
authors.forename: L
authors.initials: L
authors.lastname: Hammarström
authors.forename: M
authors.initials: M
authors.lastname: Mikelsaar
mesh_terms: D000284:Administration, Oral; D000328:Adult; D015169:Colony Count, Microbial; D005260:Female; D041981:Gastrointestinal Tract / Q000382:microbiology*; D006801:Humans; D007778:Lactobacillus; D008297:Male; D008875:Middle Aged; D019936:Probiotics / Q000008:administration & dosage* / Q000009:adverse effects / Q000493:pharmacokinetics; D055815:Young Adult